Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vaxil Bio Ltd V.VXL

Alternate Symbol(s):  VXLLF

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.


TSXV:VXL - Post by User

Bullboard Posts
Post by SleepingDWMeUpon Apr 13, 2020 6:22pm
460 Views
Post# 30905133

Spartan Bioscience

Spartan Bioscience

Spartan Bioscience receives Health Canada approval for fast, portable COVID-19 test

 
PRESS RELEASE PR Newswire 
 Apr. 13, 2020, 12:00 PM

OTTAWA, OntarioApril 13, 2020 /PRNewswire-PRWeb/ -- Ottawa's Spartan Bioscience today announced it has received Health Canada approval for its rapid, accurate and portable COVID-19 test. Approval by Health Canada means that tests can now be shipped to Spartan's federal and provincial government partners starting immediately. 

Spartan's test consists of a portable DNA analyzer called the Spartan Cube, which is the size of a coffee cup. The Cube performs the test with Spartan's COVID-19 test cartridges and proprietary swabs, manufactured in Ottawa. The automated test can be operated by non-laboratory personnel in settings such as airports, border crossings, doctors' offices, pharmacies, clinics, and remote communities. 

"We are grateful to the Government of Canada for working closely with us to expedite the review and approval process," said Paul Lem, M.D., CEO of Spartan Bioscience. "We are ready to start shipping our portable COVID-19 test to the federal and provincial governments, and to make them widely available to Canadians. There is an urgent unmet need for rapid COVID-19 testing, and as a proudly Canadian company, we are excited that our technology will be an important part of fighting the COVID-19 pandemic in Canada."

Spartan's test was developed with funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP).

Spartan's technology is currently in use by expert organizations such as the Centers for Disease Control (CDC), the New York State Department of Health, and Mayo Clinic. It has been published in prestigious medical journals including The Lancet and The New England Journal of Medicine. Spartan's technology has regulatory approvals worldwide, including FDA 510(k), European CE IVD Mark, and Health Canada.


Bullboard Posts